Evidence network for deaths_(OS)

1CheckMate 459, 20191HIMALAYA, 20221IMbrave-150, 20201COSMIC-312, 20231LEAP 002, 20231ORIENT-32, 20211CARES-310, 2023atezolizumab plus bevacizumab vs. nivolumab alone atezolizumab plus bevacizumab better 0.68 [0.48; 0.98]0.68 [0.48;0.98]atezolizumab plus bevacizumab vs. nivolumab alone atezolizumab plus bevacizumab better 0.68 [0.48; 0.98]atezolizumab plus bevacizumab vs. sorafenib atezolizumab plus bevacizumab better 0.58 [0.42; 0.80]0.58 [0.42;0.80]atezolizumab plus bevacizumab vs. sorafenib atezolizumab plus bevacizumab better 0.58 [0.42; 0.80]nivolumab alone vs. atezolizumab plus bevacizumab atezolizumab plus bevacizumab better 1.47 [1.02; 2.10]1.47 [1.02;2.10]nivolumab alone vs. atezolizumab plus bevacizumab atezolizumab plus bevacizumab better 1.47 [1.02; 2.10]nivolumab alone vs. sorafenib 0.85 [0.71; 1.01]0.85 [0.71;1.01]nivolumab alone vs. sorafenib 0.85 [0.71; 1.01]sorafenib vs. atezolizumab plus bevacizumab atezolizumab plus bevacizumab better 1.72 [1.26; 2.36]1.72 [1.26;2.36]sorafenib vs. atezolizumab plus bevacizumab atezolizumab plus bevacizumab better 1.72 [1.26; 2.36]sorafenib vs. nivolumab alone 1.18 [0.99; 1.40]1.18 [0.99;1.40]sorafenib vs. nivolumab alone 1.18 [0.99; 1.40]sorafenibplacebolenvatinibnivolumab alonedurvalumab plus bevacizumabdurvalumab plus tremelimumabatezolizumab plus bevacizumabatezolizumab plus cabozantinibpembrolizumab plus lenvatinibbevacizumabsintilimabTislelizumabVEGF(R) inhibitorcamrelizumab based treatmentnivolumab plus ipilimumab plus SoCdirect evidencenetwork meta-analysis
T vs. C sorafenibplacebolenvatinibnivolumab alonedurvalumab plus bevacizumabdurvalumab plus tremelimumabatezolizumab plus bevacizumabatezolizumab plus cabozantinibpembrolizumab plus lenvatinibbevacizumabsintilimabTislelizumabVEGF(R) inhibitorcamrelizumab based treatmentnivolumab plus ipilimumab plus SoC
sorafenib---NANA1.18
0.99; 1.40		NANA1.72
1.26; 2.36		NANANANANANANANA
placeboNA---NANANANANANANANANANANANANA
lenvatinibNANA---NANANANANANANANANANANANA
nivolumab alone0.85
0.71; 1.01		NANA---NANA1.47
1.02; 2.10		NANANANANANANANA
durvalumab plus bevacizumabNANANANA---NANANANANANANANANANA
durvalumab plus tremelimumabNANANANANA---NANANANANANANANANA
atezolizumab plus bevacizumab0.58
0.42; 0.80		NANA0.68
0.48; 0.98		NANA---NANANANANANANANA
atezolizumab plus cabozantinibNANANANANANANA---NANANANANANANA
pembrolizumab plus lenvatinibNANANANANANANANA---NANANANANANA
bevacizumabNANANANANANANANANA---NANANANANA
sintilimabNANANANANANANANANANA---NANANANA
TislelizumabNANANANANANANANANANANA---NANANA
VEGF(R) inhibitorNANANANANANANANANANANANA---NANA
camrelizumab based treatmentNANANANANANANANANANANANANA---NA
nivolumab plus ipilimumab plus SoCNANANANANANANANANANANANANANA---

pathologies: 131 - treatments: 864 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons